Molecular pathophysiology of myelodysplastic syndromes

Annual Review of Pathology: Mechanisms of Disease

Volumn 8, Issue , 2013, Pages 21-47

  Lindsley, R Coleman ^a,b   Ebert, Benjamin L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cytogenetic; Epigenetic; Mutation; RNA splicing

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; CBL PROTEIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; MESSENGER RNA; METHYLTRANSFERASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SMALL NUCLEAR RIBONUCLEOPROTEIN; SMALL NUCLEAR RNA; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 3Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DNA FLANKING REGION; DNA METHYLATION; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EPIGENETICS; EXCISION; EXCISION REPAIR; EXON; FOLLICULAR LYMPHOMA; FRAMESHIFT MUTATION; GENE; GENE FREQUENCY; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HEPATOSPLENOMEGALY; HETEROZYGOTE; HISTONE MODIFICATION; HUMAN; INTRON; ISOCHROMOSOME; JUVENILE MYELOMONOCYTIC LEUKEMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; OPEN READING FRAME; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; RNA SEQUENCE; RNA SPLICING; SF3B1 GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SPLICEOSOME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRISOMY 8; U2AF1 GENE; UNIPARENTAL DISOMY; ANIMAL; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; PHENOTYPE;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; POINT MUTATION;

MLCS; MLOWN;

EID: 84875910316     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011811-132436     Document Type: Review

References (151)

1. Brunning R, Orazi A, Germing U, Le Beau M, Porwit A, et al. 2008. Myelodysplastic syndromes/ neoplasms, overview. See Ref. 151, pp. 88-933
2. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, et al. 2012. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J. Clin. Oncol. 30:820-299
3. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, et al. 2007. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2,124 patients. Blood 110:4385-955
4. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. 2008. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534-422
5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, et al. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-888
6. Yoshida K, SanadaM, Shiraishi Y, Nowak D, Nagata Y, et al. 2011. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-699
7. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, et al. 2011. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364:2496-5066
8. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, et al. 2012. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30:3376-822
9. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, et al. 2011. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365:1384-955
10. Bacher U, Haferlach T, Schnittger S, Kreipe H, KrögerN. 2011. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br. J. Haematol. 153:149-677
11. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, et al. 2012. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 44:53-577
12. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. 2008. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40:1413-155
13. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, et al. 2008. Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-766
14. DavidCJ, Manley JL. 2010. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24:2343-644
15. Will CL, Lhrmann R. 2011. Spliceosome structure and function. Cold Spring Harb. Perspect. Biol. 3:181- 2033
16. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Porta Della MG, et al. 2011. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 118:6239-466
17. Damm F, Thol F, Kosmider O, Kade S, Löffeld P, et al. 2011. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 26:1137-400
18. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, et al. 2012. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119:569-722
19. Maratheftis CI, Bolaraki PE, Giannouli S, Kapsogeorgou EK,Moutsopoulos HM, Voulgarelis M. 2006. Aberrant alternative splicing of interferon regulatory factor 1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. Leuk. Res. 30:1177-866
20. Caudill JS, Porcher JC, Steensma DP. 2008. Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. Leuk. Lymphoma 49:989-933
21. Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann MS, Koseki H. 2005. Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes Dev. 19:536-411
22. Ball MP, Li JB, Gao Y, Lee J-H, LeProust EM, et al. 2009. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat. Biotechnol. 27:361-688
23. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:766-700
24. Ito S, Shen L, Dai Q, Wu SC, Collins LB, et al. 2011. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333:1300-33
25. Tahiliani M, Koh KP, Shen Y, PastorWA, Bandukwala H, et al. 2009. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930-355
26. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, et al. 2009. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114:3448-588
27. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, et al. 2009. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315-255
28. Shen L,Kantarjian H, Guo Y, Lin E, Shan J, et al. 2010.DNAmethylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J. Clin. Oncol. 28:605-133
29. SilvermanLR, DemakosEP, Peterson BL,KornblithAB, Holland JC, et al. 2002. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20:2429-400
30. Fenaux P, Mufti GJ, Hellstrm-Lindberg E, Santini V, Finelli C, et al. 2009. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10:223-322
31. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, et al. 2010. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363:2424-333
32. Walter MJ, Ding L, Shen D, Shao J, Grillot M, et al. 2011. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2:1153-588
33. Thol F, Winschel C, Ludeking A, YunH, Friesen I, et al. 2011. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 96:1870-733
34. Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. 2011. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25:1219-200
35. Yan X-J, Xu J, Gu Z-H, Pan C-M, Lu G, et al. 2011. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43:309-155
36. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, et al. 2012. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44:23-311
37. Langemeijer SMC, Kuiper RP, Berends M, Knops R, Aslanyan MG, et al. 2009. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41:838-422
38. Delhommeau F, Dupont S, Valle Della V, James C, Trannoy S, et al. 2009. Mutation in TET2 in HSCs. in myeloid cancers. N. Engl. J. Med. 360:2289-3011
39. Kohlmann A, Grossmann V, KleinH-U, Schindela S, Weiss T, et al. 2010. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J. Clin. Oncol. 28:3858-655
40. Abdel-Wahab O,Mullally A, Hedvat C, Garcia-Manero G, Patel J, et al. 2009. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-477
41. Metzeler KH, Maharry K, Radmacher MD, Mr özek K, Margeson D, et al. 2011. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 29:1373-811
42. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-677
43. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Valle Della V, et al. 2009. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114:3285-911
44. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gken J, et al. 2010. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116:3923-322
45. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, et al. 2010. Impaired hydroxylation of 5- methylcytosine in myeloid cancers with mutant TET2. Nature 468:839-433
46. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, et al. 2011. Ten-eleven-translocation 2 (Tet2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl. Acad. Sci. USA 108:14566-711
47. Quivoron C, Couronné L, Valle Della V, Lopez CK, Plo I, et al. 2011. Tet2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20:25-388
48. Wu H, D'Alessio AC, Ito S, Wang Z, Cui K, et al. 2011. Genome-wide analysis of 5- hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 25:679-844
49. He Y-F, Li B-Z, Li Z, Liu P, Wang Y, et al. 2011. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333:1303-77
50. Li Z, Cai X, Cai C-L, Wang J, Zhang W, et al. 2011. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118:4509-188
51. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, et al. 2011. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20:11-244
52. Viguie F, Aboura A, BouscaryD, Ramond S, Delmer A, et al. 2005. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 19:1411-155
53. Mardis ER, Ding L, Dooling DJ, Larson DE,McLellan MD, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361:1058-666
54. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, et al. 2010. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Oncol. 28:3636-433
55. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, et al. 2010. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668-744
56. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, et al. 2012. Differential prognostic effect of IDH1 versus IDH2 mutations inmyelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 26:101-55
57. Ward PS, Cross JR, Lu C, Weigert O, Abel-Wahab O, et al. 2011. Identification of additional IDH mutations associated with oncometabolite R-2-hydroxyglutarate production. Oncogene 31:3491-988
58. Xu W, Yang H, Liu Y, Yang Y,Wang P, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-300
59. Beisel C, Paro R. 2011. Silencing chromatin: comparing modes and mechanisms. Nat. Rev. Genet. 12:123- 355
60. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. 2010. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42:722-266
61. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, et al. 2010. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24:1799-8044
62. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, et al. 2010. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B cell lymphomas of germinal-center origin. Nat. Genet. 42:181-855
63. Yap DB, Chu J, Berg T, Schapira M, Cheng S-WG, et al. 2011. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity to increase H3K27 trimethylation. Blood 117:2451-599
64. Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, et al. 2012. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 119:1208-133
65. Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, MassopM, et al. 2010. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42:665-677
66. Fisher CL, Lee I, Bloyer S, Bozza S, Chevalier J, et al. 2010. Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev. Biol. 337:9-155
67. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, et al. 2010. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24:1062-655
68. Gelsi-BoyerV,Trouplin V, Roquain J, Adlaie J,Carbuccia N, et al. 2010. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br. J. Haematol. 151:365-755
69. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, et al. 2011. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood 118:6920-299
70. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, et al. 2011. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J. Clin. Oncol. 29:2499-5066
71. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, et al. 2010 Loss-of-function additional sex combs-like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115:38-466
72. Peller S, Rotter V. 2003. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum. Mutat. 21:277-844
73. Wattel E, Preudhomme C, Hecquet B, VanrumbekeM,Quesnel B, et al. 1994. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-577
74. Kita-Sasai Y, Horiike S,Misawa S,KanekoH,KobayashiM, et al. 2001. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br. J. Haematol. 115:309-122
75. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. 2001. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J. Clin. Oncol. 19:1405-133
76. Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K. 1995. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85:2189- 933
77. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, et al. 2011. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144:296-3099
78. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. 2005. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 74:47-533
79. Chen C-Y, Lin L-I,Tang J-L,Ko B-S,TsayW, et al. 2007. RUNX1 gene mutation in primarymyelodysplastic syndrome - themutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br. J. Haematol. 139:405-144
80. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. 2004. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103:2316-244
81. Niimi H, Harada H, Harada Y, Ding Y, Imagawa J, et al. 2006. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 20:635-444
82. Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, et al. 2007. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J. 26:1163-755
83. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, et al. 2008. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111:4297-3088
84. Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, et al. 2012. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia 26:303-111
85. Huang G, Zhao X,Wang L, Elf S, Xu H, et al. 2011. The ability ofMLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 118:6544-522
86. HoCY,Otterud B,LegareRD, VarvilT, Saxena R, et al. 1996. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood 87:5218-244
87. Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, et al. 2009. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113:5583-877
88. Akagi T, Ogawa S, Dugas M, Kawamata N, Yamamoto G, et al. 2009. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 94:213-233
89. Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, et al. 2012. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer 51:328-377
90. Hock H, Meade E, Medeiros S, Schindler JW, Valk PJM, et al. 2004. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev. 18:2336-411
91. Bejar R, Levine R, Ebert BL. 2011. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J. Clin. Oncol. 29:504-155
92. Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, et al. 2006. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 20:1414-211
93. Schindler JW, Van Buren D, Foudi A, Krejci O, Qin J, et al. 2009. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell 5:43-533
94. Lierman E, Cools J. 2007. ETV6 and PDGFRB: a license to fuse. Haematologica 92:145-477
95. Romana S, Poirel H, Leconiat M, Flexor M, Mauchauffe M, et al. 1995. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86:4263-699
96. Barjesteh van Waalwijk van Doorn-Khosrovani S, Spensberger D, de Knegt Y, Tang M, Lwenberg B, Delwel R. 2005. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. Oncogene 24:4129-377
97. Bains A, Luthra R,Medeiros LJ, Zuo Z. 2011. FLT3 and NPM1 mutations inmyelodysplastic syndromes. Am. J. Clin. Pathol. 135:62-699
98. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. 2007. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4,130 patients with acute myeloid leukemia. Haematologica 92:744-522
99. van Kamp H, de Pijper C, Verlaan-de Vries M, Bos JL, Leeksma CH, et al. 1992. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 79:1266-700
100. Constantinidou M, Chalevelakis G, Economopoulos T, Koffa M, Liloglou T, et al. 1997. Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value. Ann. Hematol. 74:11-144
101. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. 2005. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 19:2232-400
102. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, et al. 2009. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114:1859-633
103. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, et al. 2009. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin. Cancer Res. 15:2238-477
104. Sanada M, Suzuki T, Shih L-Y, Otsu M, Kato M, et al. 2009. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460:904-88
105. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, et al. 2008. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 68:10349-577
106. Malcovati L, PortaDella MG, PietraD, Boveri E, Pellagatti A, et al. 2009. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 114:3538-455
107. Loh ML,Martinelli S, Cordeddu V, Reynolds MG, Vattikuti S, et al. 2005. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Res. 29:459-622
108. Li L, Modi H, McDonald T, Rossi J, Yee J-K, Bhatia R. 2011. A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells. Blood 118:1504-155
109. Furukawa T, Kuboki Y, Tanji E, Yoshida S, Hatori T, et al. 2011. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 1:1611
110. Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, et al. 2009. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS ONE 4:e45833
111. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, et al. 2009. Accurate detection of uniparental disomy and microdeletions by SNP array analysis inmyelodysplastic syndromes with normal cytogenetics. Leukemia 23:1605-133
112. Kantarjian H, OBrien S, Ravandi F, Borthakur G, Faderl S, et al. 2009. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS? Cancer 115:5202-99
113. Möllgård L, Saft L, TreppendahlMB, Dybedal I, N?gaard JM, et al. 2011. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica 96:963-711
114. Ades L, Boehrer S, Prbet T, Beyne-Rauzy O, Legros L, et al. 2009. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 113:3947-522
115. Jerez A, Gondek LP, Jankowska AM, Makishima H, Przychodzen B, et al. 2012. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J. Clin. Oncol. 30:1343-499
116. Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, et al. 2008. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 111:3859-622
117. Van den BergheH, Cassiman JJ, DavidG, Fryns JP,Michaux JL, SokalG. 1974. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251:437-388
118. Boultwood J, Fidler C, Strickson AJ, Watkins F,Gama S, et al. 2002. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 99:4638-411
119. Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, et al. 2007. Gene expression profiling of CD34+ cells in patients with the 5q-syndrome. Br. J. Haematol. 139:578-899
120. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, et al. 2008. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451:335-399
121. Narla A, Ebert BL. 2010. Ribosomopathies: human disorders of ribosome dysfunction. Blood 115:3196- 2055
122. McGowan KA, Pang WW,Bhardwaj R, Perez MG, Pluvinage JV, et al. 2011. Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome. Blood 118:3622-333
123. Dutt S, Narla A, Lin K, Mullally A, AbayasekaraN, et al. 2011. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 117:2567-766
124. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, et al. 2010. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat. Med. 16:59- 666
125. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, et al. 2010. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat. Med. 16:49-588
126. Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, et al. 2011. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q-syndrome. Blood 118:4666-733
127. Lane SW, Sykes SM, Al-Shahrour F, Shterental S, PaktinatM, et al. 2010. The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood 115:3489-977
128. List A, Dewald G, Bennett J, Giagounidis A, Raza A, et al. 2006. Lenalidomide in the myelodysplastic syndrome with chromosome 5q-deletion. N. Engl. J. Med. 355:1456-655
129. Fenaux P, Giagounidis A, Selleslag D, Beyne-RauzyO,Mufti G, et al. 2011. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118:3765-766
130. Tehranchi R,Woll PS, Anderson K, Buza-Vidas N, Mizukami T, et al. 2010. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N. Engl. J. Med. 363:1025-377
131. Jdersten M, Saft L, Pellagatti A, Göhring G, Wainscoat JS, et al. 2009. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 94:1762-666
132. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. 2004. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104:1474-811
133. Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA, Green ED. 1996. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88:1930-355
134. Wong JCY, Zhang Y, Lieuw KH, Tran MT, Forgo E, et al. 2010. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found inmyeloid malignancies. Blood 115:4524-322
135. Heuser M, Yap DB, LeungM, de Algara TR, Tafech A, et al. 2009. Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood 113:1432-433
136. Schanz J, Steidl C, Fonatsch C, Pfeilst öckerM,NösslingerT, et al. 2011. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J. Clin. Oncol. 29:1963-700
137. Nilsson L, Astrand-Grundstrm I, Anderson K, Arvidsson I, Hokland P, et al. 2002. Involvement and functional impairment of the CD34+CD38Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100:259-677
138. Sloand EM, Pfannes L, ChenG, Shah S, Solomou EE, et al. 2007. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 109:2399-4055
139. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, et al. 2005. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106:841-511
140. Sloand EM,Melenhorst JJ, Tucker ZCG, Pfannes L, Brenchley JM, et al. 2011.Tcell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 117:2691- 999
141. Nucifora G, Laricchia-Robbio L, Senyuk V. 2006. EVI1 and hematopoietic disorders: history and perspectives. Gene 368:1-111
142. Buonamici S, Li D, Chi Y, Zhao R, Wang X, et al. 2004. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Investig. 114:713-199
143. McClure RF, Dewald GW, Hoyer JD, Hanson CA. 1999. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br. J. Haematol. 106:445-544
144. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, et al. 2012. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/ myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118:2879-888
145. MacGrogan D, Kalakonda N, Alvarez S, Scandura JM, Boccuni P, et al. 2004. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes Chromosomes Cancer 41:203-133
146. Streubel B, Sauerland C,HeilG, FreundM, Bartels H, et al. 1998. Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL orMDS and abnormalities of the short arm of chromosome 12. Br. J. Haematol. 100:521-333
147. Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, et al. 2012. Evaluation of dysplasia through detailed cytomorphology in 3,156 patients from the D?usseldorf Registry on myelodysplastic syndromes. Leuk. Res. 36:727-344
148. Orazi A, Czader MB. 2009. Myelodysplastic syndromes. Am. J. Clin. Pathol. 132:290-3055
149. Vardiman J, Bennett J, Bain B, Baumann I, Thiele J, Orazi A. 2008. Myelodysplastic/myeloproliferative neoplasm, unclassifiable. See Ref. 151, pp. 85-866
150. Orazi A, Bennett J, GermingU, Brunning R, Bain B, Thiele J. 2008. Chronicmyelomonocytic leukemia. See Ref. 151, pp. 76-799
151. Swerdlow SH, Carrigo E, HarrisNL, Jaffe ES, Pilori SA, et al., eds. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, Fr.: IARCC